Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients-Reference-Cited by-同舟云学术

Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients

Published:2019-07 Issue: Volume:69 Page:8-14
ISSN:0009-9120
Container-title:Clinical Biochemistry
language:en
Short-container-title:Clinical Biochemistry

Author:

Naito Takafumi^ORCID,Ohshiro Junya,Sato Hikaru,Torikai Eiji,Suzuki Motohiro,Ogawa Noriyoshi,Kawakami Junichi

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Clinical Biochemistry,General Medicine

Reference42 articles.

1. Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus)1;Almawi;Cell Transplant.,2001

2. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study;Kremer;Arthritis Rheum.,2003

3. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial;Yocum;Arthritis Rheum.,2003

4. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics;Iwasaki;Drug Metab. Pharmacokinet.,2007

5. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus;Hesselink;Clin. Pharmacol. Ther.,2003

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders;Drug Metabolism and Pharmacokinetics;2024-07

2. Not your usual drug‐drug interactions: Monoclonal antibody–based therapeutics may interact with antiseizure medications;Epilepsia;2021-12-29

3. Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism;Transplant International;2021-07-08

4. Impact of Interferons and Biological Drug Inhibitors of IL-2 and IL-6 on Small-Molecule Drug Metabolism Through the Cytochrome P450 System;Annals of Pharmacotherapy;2021-06-02

5. Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients;Basic & Clinical Pharmacology & Toxicology;2019-11-15